- Multiple Hereditary Exostosis (MHE), a rare genetic disorder characterized by the development of multiple benign bone tumors, is gaining increasing attention in North America due to advances in diagnostic technologies, growing disease awareness, and the expansion of specialized treatment centers
- The rising demand for early diagnosis and tailored therapeutic approaches is primarily fueled by enhanced access to genetic testing, supportive healthcare policies, and increased focus on rare disease management by public and private sectors
- U.S. dominated the North America multiple hereditary exostosis market with the largest revenue share of 45.8% in 2024, driven by a strong healthcare infrastructure, active rare disease research programs, and the presence of leading biopharmaceutical companies engaged in orphan drug development and clinical trials
- Canada is expected to be the fastest growing country in the North America multiple hereditary exostosis market during the forecast period due to rising awareness initiatives, expanded rare disease registries, and growing access to specialized healthcare services
- The genetic tests segment dominated the North America multiple hereditary exostosis market with a market share of 49.2% in 2024, attributed to its essential role in early detection, family screening, and enabling individualized treatment plans
